According to the Smart Finance APP, Ark Pharmacy (06086) fell more than 44% yesterday and rebounded more than 20% this morning. The current stock price is still 30% lower than the issuance price. As of press time, it rose 17% to HK$5.3 with a turnover of 11.1438 million HK dollars.
Ark Pharmacy focuses on the management of chronic diseases (hypertension, cardiovascular disease, respiratory system and other chronic diseases), providing comprehensive management services for chronic diseases and online retail pharmacy services through the Jianke platform. According to the data of Zhuo Shi Consulting, based on the average monthly active users in 2023, the company is China's largest online chronic disease management platform.
In terms of finance, the company's annual losses from 2021 to 2023 were RMB 0.304 billion, RMB 0.383 billion, and RMB 0.197 billion, and the accumulated losses in the three years were nearly RMB 0.9 billion. In addition, the prospectus stated that the company is expected to continue to lose money in 2024. In addition, the company did not introduce cornerstone investors in this listing, and the company's public shareholder holdings were only 1.78%, which is called a "beggar among beggars".